DoD funds Biovest, pushing vax-making tech

U.S. Department of Defense efforts are continuing to advance vaccine manufacturing. The department is currently funding Biovest International, to the tune of $1.5 million, to develop fast and cost-effective biomanufacturing solutions for vaccines to ward off and treat infectious diseases and cancers.

The work involves adapting Biovest's automated bioreactor system into a rapid viral vaccine production platform, according to an announcement. DoD and Biovest researchers are currently studying virus propagation on the AutoVAX ID bioreactor, which was developed as a commercial GMP-compliant platform for the manufacture of personalized cancer vaccines. The researchers are evaluating the platform for use in cell-culture based production of viral vaccines, including influenza.

As we reported Tuesday, another DoD-funded effort resulted in speedy 12-week production for a swine flu vaccine, from receipt of an unknown target amino acid sequence to scaled-up production. That effort included expression technology from Pfenex and the single-use FlexFactory production platform from Xcellerex.

- here's the Biovest release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.